Distinguishing tumor vs. clonal hematopoiesis (CH)–derived TP53 and BRCA1/2 alterations in ovarian cancer liquid biopsies with a predictive algorithm to inform clinical decision-making.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.5592
Abstract: 5592 Background: CH results from mutations in hematopoietic stem cells and can occur in clinically relevant genes that are detected in liquid biopsy (LBx) of solid tumor patients. TP53 and less frequently BRCA1/2 can be… read more here.
Keywords: mut; tumor; brca1 mut; tp53 mut ... See more keywords